Ardelyx
IPO
- Headquarters
- Fremont, California
- Employees
- 201–500
- Founded
- 2007
- Business Model
- B2B
- Website
- ardelyx.com
- Total Funding
- $140.0M
- Last Round
- $110.0M Private EquityJul 2016
About
Ardelyx (Nasdaq: ARDX) is a biopharmaceutical company dedicated to developing first-in-class medicines that improve the lives of people living with kidney disease and gastrointestinal conditions. The company's lead approved product, XPHOZAH (tenapanor), is an FDA-approved treatment for hyperphosphatemia in adults with chronic kidney disease on dialysis.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account